Lyrica

Neuropathic pain in adults, including neuropathic pain associated w/ spinal cord injury. Generalized anxiety disorder (GAD) in adults. Management of fibromyalgia. Adjunctive therapy in adults w/ partial seizures, w/ or w/o secondary generalization.

Neuropathic pain Initially 150 mg daily, may be increased to 300 mg daily after an interval of 3-7 days. Max: 600 mg daily after an additional 7-day interval. Fibromyalgia Dose range: 300-450 mg daily given in 2 divided doses. Initially 75 mg bid, may be increased to 150 mg bid w/in 1 wk. May be further increased to 225 mg bid. Max: 600 mg daily after an additional wk. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max: 600 mg daily after an additional wk. GAD Dose range: 150-600 mg daily given in 2 or 3 divided doses. Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Following an additional wk, dose may be increased to 450 mg daily. Max: 600 mg daily after an additional wk. Renal impairment CrCl ≥60 mL/min Initially 150 mg daily in 2 or 3 divided doses. Max: 600 mg daily, ≥30-<60 mL/min Initially 75 mg daily given in 2 or 3 divided doses. Max: 300 mg daily, ≥15-<30 mL/min Initially 25-50 mg daily as a single or in 2 divided doses. Max: 150 mg daily, <15 mL/min Initially 25 mg daily as a single dose. Max: 75 mg daily. Supplementary dosage following hemodialysis Initially 25 mg daily as a single dose, given immediately following every 4-hr hemodialysis. Max: 100 mg daily.

May be taken with or without food.

Hypersensitivity.

Discontinue immediately if symptoms of angioedema occur. Should not be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Adjust hypoglycemic medications in diabetic patients who gain wt. Associated w/ dizziness & somnolence which could increase the occurrence of accidental injury (fall). Loss of consciousness, confusion, mental impairment; transient visual blurring & other changes in visual acuity. W/drawal symptoms after discontinuation of short- & long-term treatment. Evaluate patients for history of drug abuse & observe for signs of misuse or abuse (eg, development of tolerance, dose escalation, drug-seeking behavior). Patients w/ severe CHF. Concomitant use w/ opioids. May influence the ability to drive or use machines. Women of childbearing potential must use effective contraception. May cause major birth defects in the unborn child in the 1st trimester of pregnancy. Not recommended during lactation. Not recommended in childn <12 yr & adolescents (12-17 yr). Elderly >65 yr may require dose reduction due to decreased renal function.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paresthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back pain, limb pain, cervical spasm; peripheral edema, edema, abnormal gait, fall, feeling drunk/abnormal, fatigue; increased wt. Headache. Nausea, diarrhea.

May potentiate effects of ethanol & lorazepam. Additive in the impairment of cognitive & gross motor function caused by oxycodone. Resp failure, coma & death w/ other CNS depressants. Reduced lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) w/ potentially constipation-producing medications eg, opioid analgesics.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

Rx